Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety of S 38093 in mild to moderate Alzheimer's disease
2010-024626-37Phase 2Completed
- Sponsor
- Servier
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of S-38093 in Alzheimer's disease (AD) (4 arms), sponsored by Servier. Primary endpoint: ADAS-Cog 11-items. Started Jul 2011; status: completed.
02
Drugs
S-38093
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2010-024626-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024626-37.